CN102797043B - 药物分子片段库及其构建方法 - Google Patents
药物分子片段库及其构建方法 Download PDFInfo
- Publication number
- CN102797043B CN102797043B CN201110137502.5A CN201110137502A CN102797043B CN 102797043 B CN102797043 B CN 102797043B CN 201110137502 A CN201110137502 A CN 201110137502A CN 102797043 B CN102797043 B CN 102797043B
- Authority
- CN
- China
- Prior art keywords
- acid
- methyl
- amino
- phenyl
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110137502.5A CN102797043B (zh) | 2011-05-23 | 2011-05-23 | 药物分子片段库及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110137502.5A CN102797043B (zh) | 2011-05-23 | 2011-05-23 | 药物分子片段库及其构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102797043A CN102797043A (zh) | 2012-11-28 |
CN102797043B true CN102797043B (zh) | 2015-11-25 |
Family
ID=47196331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110137502.5A Active CN102797043B (zh) | 2011-05-23 | 2011-05-23 | 药物分子片段库及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102797043B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017172824A1 (en) * | 2016-03-28 | 2017-10-05 | University Of Delaware | Poly(aryl piperidinium) polymers for use as hydroxide exchange membranes and ionomers |
CN108072684B (zh) * | 2016-11-11 | 2020-06-16 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
CN110963996B (zh) * | 2017-10-25 | 2022-09-09 | 西南大学 | 含苯乙酮取代基的靛红唑醇类化合物及其制备方法和医药应用 |
JPWO2022024649A1 (zh) * | 2020-07-30 | 2022-02-03 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1668918A (zh) * | 2002-07-24 | 2005-09-14 | 基德姆生物科学有限公司 | 药物发现的方法 |
CN1955715A (zh) * | 2004-10-25 | 2007-05-02 | 弗·哈夫曼-拉罗切有限公司 | 配体-受体示踪测定法 |
-
2011
- 2011-05-23 CN CN201110137502.5A patent/CN102797043B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1668918A (zh) * | 2002-07-24 | 2005-09-14 | 基德姆生物科学有限公司 | 药物发现的方法 |
CN1955715A (zh) * | 2004-10-25 | 2007-05-02 | 弗·哈夫曼-拉罗切有限公司 | 配体-受体示踪测定法 |
Also Published As
Publication number | Publication date |
---|---|
CN102797043A (zh) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Discovery and structure− activity relationship of 3-aryl-5-aryl-1, 2, 4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents | |
Aguilar et al. | Discovery of 4-((3′ R, 4′ S, 5′ R)-6 ″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2 ″-oxodispiro [cyclohexane-1, 2′-pyrrolidine-3′, 3 ″-indoline]-5′-carboxamido) bicyclo [2.2. 2] octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development | |
Liu et al. | Quinoxalin-2 (1 H)-one derivatives as inhibitors against hepatitis C virus | |
CN102797043B (zh) | 药物分子片段库及其构建方法 | |
Woll et al. | Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 as a treatment for spinal muscular atrophy | |
Hour et al. | 6-Alkylamino-and 2, 3-Dihydro-3 ‘-methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization | |
Liu et al. | Synthesis, preliminary structure–activity relationships, and in vitro biological evaluation of 6-aryl-3-amino-thieno [2, 3-b] pyridine derivatives as potential anti-inflammatory agents | |
Dyrager et al. | Design, synthesis, and biological evaluation of chromone-based p38 MAP kinase inhibitors | |
Timiri et al. | Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors | |
Sharma et al. | Synthesis and structure–activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2 | |
Meguellati et al. | B-ring modified aurones as promising allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase | |
CN101282934A (zh) | 三芳基羧酸衍生物 | |
Sun et al. | Synthesis and evaluation of a new series of substituted acyl (thio) urea and thiadiazolo [2, 3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase | |
JP2010504957A5 (zh) | ||
CN102939088A (zh) | 抗病毒化合物 | |
CA2453175A1 (en) | Interaction inhibitors of tcf-4 with beta-catenin | |
Vitale et al. | 5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4 | |
Tseng et al. | Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives | |
Kavitha et al. | An efficient one-pot four-component Gewald reaction: Synthesis of substituted 2-aminothiophenes with coumarin–thiazole scaffolds under environmentally benign conditions | |
Spanò et al. | An overview on chemical structures as ΔF508-CFTR correctors | |
Cuisiat et al. | Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities | |
CN100434425C (zh) | 4-喹唑啉酮衍生物及其在抗肿瘤药物中的应用 | |
Sindac et al. | Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication | |
Carta et al. | A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems | |
Dorsey et al. | Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Cheng Inventor after: Zhou Honggang Inventor after: Sun Tao Inventor before: Yang Cheng Inventor before: Miao Zhiwei Inventor before: Sun Bo Inventor before: Yang Meng Inventor before: Liu Wei Inventor before: Zhou Honggang Inventor before: Lou Zhiyong Inventor before: Yang Chengmiao, Zhi Wei, Sun Bo, Yang Meng, Liu Wei, Zhou Honggang, Lou Zhiyong, Liu Zhijie |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150925 Address after: 300190, room 3, 350 Longchuan Road, Tianjin, Nankai District Applicant after: Tianli (Tianjin) Technology Co., Ltd. Address before: 300457 No. 220, Dongting Road, Tianjin economic and Technological Development Zone, seven floor, experimental building, Tianjin international biological medicine Joint Research Institute, S705 Applicant before: CBB Network Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210323 Address after: Room 101, door 3, building B25, entrepreneurship headquarters base, North Fuyuan Road, Wuqing District, Tianjin Patentee after: Tianjin Jikun Pharmaceutical Technology Co.,Ltd. Address before: Room 350, No.3, Longchuan Road, Nankai District, Tianjin 300190 Patentee before: TIANLIKANG (TIANJIN) TECHNOLOGY Co.,Ltd. |